|
WASHINGTON (AP) - Johnson & Johnson won federal approval Wednesday for a schizophrenia drug derived from another top-selling anti-psychotic medicine.
The Food and Drug Administration said Invega will add to the treatment options for the disabling mental disorder, which affects about 2 million Americans.
It also could add to the bottom line for J&J, which faces the loss of patent protection in December 2007 for the No. 3 anti-psychotic drug, Risperdal. Risperdal, also called risperidone, had $2.3 billion in sales in 2005, according to the pharmaceutical data company IMS Health.
|